Out-licensing

A therapeutically active polypeptide is covalently attached directly to vitamin B12 or via a spacer. The pharmaceutical composition can be in the form of a capsule, tablet, emulsion, colloidal dispersion, elixir, gel, gum, or paste.

Presently over 60% of adults in the U.S. are considered obese, but current anti-obesity drugs produce an average placebo-subtracted weight loss of only 5%. In addition, obesity can result in other diseases, such as heart disease and diabetes. Diabetes patients rely on invasive insulin delivery methods for the treatment of their disease.

Previous research using oral insulin delivery has demonstrated an insulin bioavailability of only 5% due to proteolysis of the drug in the gastrointestinal tract and poor absorption from the intestine into the blood. This invention discloses an oral delivery conjugate comprising vitamin B12 coupled to a therapeutically active polypeptide. Insulin, peptide YY, or glucagon-like peptide can be used as the therapeutic agent to treat diabetes or obesity.
The technology has several advantages in that it is non-invasive and provides enhanced drug bioavailability. It also proficiently transports across the blood-brain barrier and causes no side-effects.

Early Stage

Syracuse University actively seeks to partner with businesses for purposes of building expertise, expanding your IP portfolio, licensing, and other opportunities for university/industry collaboration.